Virpax Pharmaceuticals, Inc.
VRPX · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $40 | $81 | $25 | $123 |
| - Cash | $2 | $0 | $2 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $39 | $81 | $23 | $121 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$2 | -$3 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.8 | -0.43 | -1.75 | -2.75 |
| % Growth | -86% | 75.4% | 36.4% | – |
| Operating Cash Flow | -$3 | -$4 | -$2 | -$8 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$4 | -$2 | -$8 |